Analysis of the influence of decrease of L-asparaginase activity and hypersensitivity reaction on the treatment outcome in children with acute lymphoblastic leukemia

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Unknown venue

• Publication date

  2014-03-20

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The anti-asparagines antibodies correlate with l-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia

  2007cited by this paper
• A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.

  2006cited by this paper
• Development of anti‐asparaginase antibodies in childhood acute lymphoblastic leukemia

  2004cited by this paper
• MONITORING THE ASPARAGINASE ACTIVITY AND ASPARAGINE LEVELS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKAEMIA TREATED WITH DIFFERENT ASPARAGINASE PREPARATIONS

  2004cited by this paper
• l-Asparagine depletion levels and l-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment

  2004cited by this paper
• Asparaginase Antibody and Asparaginase Activity in Children With Higher-Risk Acute Lymphoblastic Leukemia: Children's Cancer Group Study CCG-1961

  2004cited by this paper
• The best way to use asparaginase in childhood acute lymphatic leukaemia – still to be defined?

  2004influential reference
• Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients

  2003cited by this paper
• A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.

  2002cited by this paper
• Drug monitoring of low‐dose PEG‐asparaginase (Oncaspartm) in children with relapsed acute lymphoblastic leukaemia

  2001cited by this paper
• Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL‐BFM 95 reinduction treatment

  2001influential reference
• L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure.

  2000cited by this paper
• Pegylated asparaginase (OncasparTM) in children with ALL: drug monitoring in reinduction according to the ALL/NHL‐BFM 95 protocols

  2000cited by this paper
• Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia.

  2000influential reference
• Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia

  1998cited by this paper
• L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase.

  1996cited by this paper
• Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.

  1996cited by this paper
• Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement.

  1986cited by this paper
• L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans.

  1981cited by this paper
• Hypersensitive reactions and antibody formation during L‐asparaginase treatment of children and adults with acute leukemia

  1976cited by this paper

• No citing papers are available for this paper.